Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Chesney, Jason; Puzanov, Igor; Collichio, Frances; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore F.; Hauschild, Axel; Lebbe, Celeste; Chen, Lisa; Kim, Jenny J.; Gansert, Jennifer; Andtbacka, Robert H. I.; Kaufman, Howard L.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Autor(en):

Chesney, Jason; Puzanov, Igor; Collichio, Frances; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore F.; Hauschild, Axel; Lebbe, Celeste; Chen, Lisa; Kim, Jenny J.; Gansert, Jennifer; Andtbacka, Robert H. I.; Kaufman, Howard L.

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Journal of Clinical Oncology (2018), Bd. 36, H. 17, S. 1658-1667

Verlagsangabe:

Amer Soc Clinical Oncology

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.2017.73.7379

ISSN:

1527-7755